General Electric Company and Eli Lilly and Company Announce Research Collaboration to Co-Develop Molecular In Vitro Diagnostics for Cancer Treatments

NISKAYUNA, N.Y. & INDIANAPOLIS--(BUSINESS WIRE)--GE Global Research, the General Electric Company’s (NYSE:GE) centralized research and development organization, and GE Healthcare today announced a three-year collaborative research agreement with Eli Lilly and Company (NYSE:LLY) to discover and develop advanced in vitro diagnostic assays that may predict cancer treatment response to targeted therapies.
MORE ON THIS TOPIC